Charles River Laboratories International (NYSE:CRL) is scheduled to be posting its Q2 2013 quarterly earnings results after the market closes on Wednesday, July 31st. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, May 1st. The company reported $0.69 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by $0.02. The company had revenue of $291.20 million for the quarter, compared to the consensus estimate of $294.53 million. During the same quarter in the previous year, the company posted $0.70 earnings per share. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. Charles River Laboratories International has set its FY13 guidance at $2.80-2.90 EPS. On average, analysts expect Charles River Laboratories International to post $2.82 EPS for the current fiscal year and $3.07 EPS for the next fiscal year.
Charles River Laboratories International (NYSE: CRL) opened at 44.70 on Tuesday. Charles River Laboratories International has a 52-week low of $33.70 and a 52-week high of $46.90. The stock’s 50-day moving average is currently $42.94. The company has a market cap of $2.192 billion and a price-to-earnings ratio of 22.38.
CRL has been the subject of a number of recent research reports. Analysts at Goldman Sachs Group Inc. reiterated a “sell” rating on shares of Charles River Laboratories International in a research note to investors on Tuesday, July 23rd. They now have a $38.00 price target on the stock. On a related note, analysts at Jefferies Group raised their price target on shares of Charles River Laboratories International from $50.00 to $52.00 in a research note to investors on Tuesday, July 23rd. They now have a “buy” rating on the stock. Finally, analysts at Ned Davis Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note to investors on Monday, July 1st.
Three analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $44.95.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
